1382 / 1674
Endpoint: Second Sarcomas
Overall number of studies:
Total number of Patients:
Second Sarcomas:
Treatment years:
Range of FU:
7.46 (1.02-54.54)
6
(46,176)
Schaapveld 2008, <50 y
Schaapveld 2008, >50 y
Kirova 2007
(43,390)
(14,678)
(16,705)
Mery 2009, incl. DCIS
(563,155)
Grantzau 2012
TOTAL; I
2
= 49%
Studies, number of pt.
0.5 1 2 4 5
2.82 (0.34-23.34)
6
3.43 (1.46-8.05)
21
1.54 (1.31-1.81)
45
2.96 (1.29-6.80)
22
2.41 (1.41-4.13) 100
RT
41%
NON-RT
59%
5
684,104
1,048
1973 to 2007
1 to 26 years
RT decreased risk
RT
increased
risk
Relative Risk (95% CI) IV Random
RR ES (95 CI%); Weight %
Grantzau 2012
Berrington d Gonzalez, 2010 (192,057)
Latency ≥ 5 years
(26,598)
TOTAL; I
2
= 0%
2.52 (1.67-3.81)
84
2.61 (1.02-6.68)
16
2.53 (1.74-3.70) 100